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& Abstract: We sought to assess the extent to which pain
relief in chronic back and leg pain (CBLP) following spinal
cord stimulation (SCS) is influenced by patient-related
factors, including pain location, and technology factors.
A number of electronic databases were searched with
citation searching of included papers and recent systematic
reviews. All study designs were included. The primary
outcome was pain relief following SCS, we also sought pain
score (pre- and post-SCS). Multiple predictive factors were
examined: location of pain, history of back surgery, initial
level of pain, litigation/worker’s compensation, age, gender,
duration of pain, duration of follow-up, publication year,
continent of data collection, study design, quality score,
method of SCS lead implant, and type of SCS lead. Between-
study association in predictive factors and pain relief were
assessed by meta-regression. Seventy-four studies (N = 3,025
patients with CBLP) met the inclusion criteria; 63 reported
data to allow inclusion in a quantitative analysis. Evidence of
substantial statistical heterogeneity (P < 0.0001) in level of
pain relief following SCS was noted. The mean level of pain
relief across studies was 58% (95% CI: 53% to 64%, random
effects) at an average follow-up of 24 months. Multivariable
meta-regression analysis showed no predictive patient or
technology factors. SCS was effective in reducing pain
irrespective of the location of CBLP. This review supports
SCS as an effective pain relieving treatment for CBLP with
predominant leg pain with or without a prior history of back
surgery. Randomized controlled trials need to confirm the
effectiveness and cost-effectiveness of SCS in the CLBP
population with predominant low back pain. &
Key Words: spinal cord stimulation, back pain, systematic
review, meta-regression analysis, predictive factors, out-
comes
BACKGROUND
Randomized controlled trials have shown spinal cord
stimulation (SCS) to be a clinically effective adjunct to
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medical management and an alternative to a further
operation in individuals with chronic back and leg pain
(CBLP), whom have undergone previous back surgery,
so-called “failed back surgery syndrome” (FBSS).1,2
Through improved pain relief, SCS provides important
enhancement to the functionality and health-related
quality of life of those with CBLP.3 The National
Institute for Health and Care Excellence (NICE) in the
United Kingdom recently reviewed these trials and
evidence of cost-effectiveness.4–6 On the basis of their
review, NICE recommended SCS as a treatment for
patients suffering from refractory chronic neuropathic
pain conditions, including CBLP.7
Chronic back and leg pain (CBLP) represents a poorly
defined group of pain conditions, ranging from chronic
low back (axial) pain to persistent hip, buttock and leg
(radicular) pain syndromes, but often consists of a
combination of both.8 CBLP consists of both back and
leg pain and is differentiated here from CLBP. Greater
success of SCS in treatment of radicular pain has been
reported than with axial low back pain;9,10 however,
both randomized controlled trials of SCS in FBSS
recruited only those individuals who presented with
predominant leg pain, excluding those with a chief
complaint of axial pain exceeding radicular pain.1,2 A
meta-analysis of cases series in CBLP noted a substantial
level of heterogeneity in the level of pain relief following
SCS.11 Although the authors of this analysis examined a
number of predictive factors that may influence the
differing degree of pain relief, they did not consider pain
location, that is, whether pain was predominantly leg or
back in origin. With the continued technological devel-
opment of SCS (eg, number of electrodes, electrode
configurations, programming options), there is a grow-
ing interest in understanding how these innovations
impact on the level of pain relief experienced by patients
with CBLP.12–14
The aim of this study was to examine the predictive
value of patient-related factors, including leg versus
back pain location and whether patients have undergone
previous back surgery (FBSS), as well as SCS technology-
related factors.
METHODS
This review was carried out and reported in
accordance with the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
statement.15
Literature Searches
Studies were initially identified from a previous system-
atic review undertaken by some of the authors (RST,
RJT).11 This list of studies was updated by searching the
following electronic databases from the end date of the
previous review (ie, January 2002) up to June 2012:
MEDLINE (Ovid), MEDLINE InProcess (Ovid), EM-
BASE (Ovid), Cochrane Library (Cochrane Central
Register of Controlled Trials [CENTRAL], Databases
of Abstracts of Reviews of Effects [DARE], Health
Technology Assessment [HTA] database, NHS Eco-
nomic Evaluation Database [NHSEED]; Wiley). The
search strategy was developed to maximize sensitivity of
article identification and was not restricted by language,
or any other limits (see Appendix S1). Current con-
trolled trials registers (metaRegister of Controlled Trials
ISRCTN database, metaRegister of Controlled Trials,
UK Clinical Research Network Portal, World Health
Organisation International Clinical Trials Research
Portal and ClinicalTrials.gov) were searched for infor-
mation on current or recently completed studies. Cita-
tion lists of included papers and recent systematic
reviews were checked for additional references.16–18
Issues of the journal “Neuromodulation” were hand
searched up to September 2012. Two reviewers (RST
and RJT) independently scanned all the titles and
abstracts and identified potentially relevant articles to
be retrieved. Where there was uncertainty, full-text
copies of papers were obtained.
Inclusion and Exclusion Criteria
Studies were considered eligible if they fulfilled the
following criteria:
 Population—adults with CBLP, who present with
predominant leg pain, predominant back pain, or
mixed leg and back pain, irrespective of whether
they have undergone prior back surgery or not.
 Intervention—SCS.
 Comparator—none or any comparative therapy.
 Outcomes—our primary outcome was the pro-
portion of patients achieving pain relief. Pain
outcome reported as a continuous score was a
secondary outcome.
Studies were excluded on the basis of: combining SCS
with other interventional procedures, such as intrathecal
drug delivery or other types of neurostimulation,
reporting of only technical outcomes (ie, device settings
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or stimulation protocols or parasthesia coverage) and no
pain-related outcomes, mixed case series (ie, recruit
patients from a number of indication groups) where only
aggregated results were reported, single case reports or
case reports, studies published as abstracts only; and
non-English language publications.
Data Extraction
The following categories of information were extracted
from included studies: study population baseline char-
acteristics (eg, age, gender, duration and location of
pain); (2) SCS intervention (ie, use of test screen, type of
internal implant generator, lead and placement method,
stimulation parameters); study characteristics (eg, study
design, country of publication, length of follow-up); and
outcome results. Where studies assessed outcomes
at more than one follow-up, we extracted the latest
follow-up.
Study Quality Assessment
In accord with a previous systematic review,11 the
following five factors were considered in the assessment
of study quality: (1) prospective study design; (2)
consecutive patient sampling; (3) explicit statement of
patient inclusion/exclusion criteria; (4) losses to follow-
up; and (5) blinded/independent assessment of outcome.
Data extraction and quality assessment were undertaken
by a single reviewer (RJT) using a standardized form and
verified by a second reviewer (RST). Any disagreements
were resolved by consensus.
Data Synthesis and Analysis
Quantitative data analysis focused on the primary
outcome, that is, the proportion of patients experiencing
pain relief following SCS. In the case of controlled
studies, only the SCS arm was used. For each study, pain
relief was expressed as a percentage and the 95%
confidence interval calculated (based on an exact bino-
mial distribution). Results were pooled across studies
using meta-analysis methods using the inverse variance
approach.19,20
Heterogeneity among studies was first explored
qualitatively (by comparison of the characteristics of
included studies) and quantitatively (using the v2 test of
heterogeneity and I2 statistic). Given that both the level
of clinical and statistical heterogeneity were seen (ie, v2
test of heterogeneity < 0.05 and I2 statistic > 50%), the
DerSimonian Laird random-effects method was used to
pool studies.21,22 Rather than simply calculate a single
overall pooled estimate of the effectiveness of SCS, the
primary aim of analysis was to explore heterogeneity
and assess the patient and technology-related factors
that were associated with SCS pain relief. The funnel
plot was examined and Egger et al.’s test calculated to
examine the likely presence of publication bias and
small-study effect.23
A “between-study” analysis used meta-regression to
examine the influence of the following prespecified study
level factors: initial level of pain (mean pain score) type
of CBLP (predominant back pain vs. predominant leg
pain vs. mixed leg and back pain; CBLP with history of
back pain surgery vs. CBLP with no history of back pain
surgery); age (mean); gender (% male); duration of pain
(mean); duration of follow-up (mean); litigation/work-
er’s compensation; year of publication; continent of data
collection (North America vs. Europe vs. other); study
setting (single vs. multicenter); SCS intervention (surgi-
cal vs. percutaneous leads, quadripolar vs. octapolar
vs.16-contacts); study design (RCT or non-RCT vs. case
series); and quality score. These factors were assessed in
both a univariable and multivariable model with P value
adjustment for multiple testing.24
Studies reporting continuous pain scores (either as
visual analog scale [VAS] or numerical rating scale
[NRS]) were separately pooled using meta-analysis as
pre- and post-SCS change scores. In accord with
recommended methods for pooling pain outcomes,
where necessary, pain scores were transformed, so all
studies were expressed on a 0–10 scale.11,25,26 Where
not reported, standard deviation for change was calcu-
lated using pre- and post-SCS standard deviations
(assuming a within-study correlation coefficient of
0.9).20
A number of studies reported the association between
patient-related and technology-related factors and SCS
pain relief. The results of these “within-study” analyses
were tabulated and reported descriptively. All quantita-
tive analyses were performed using STATA v.11.1 (Stata
Corp., College Station, TX, U.S.A.).
RESULTS
Identification and Selection of Studies
Our previous systematic review included a total of 78
studies of which 21 studies were judged not to meet the
revised inclusion criteria of this present review.11 The
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main reasons for exclusion were non-English language
and abstract only publications.
The electronic searches for this updated review
yielded a total of 992 titles, of which 18 new studies
were included. Therefore, a total of 74 studies (77
publications) were included, of which 68 were case
series, four were RCTs, and two were comparative
studies using a nonrandomized design. The selection
process is summarized in Figure 1 (citations of studies
included and excluded on the basis of full paper review
are listed in Appendix S2). The characteristics of the
included studies are summarized in Table 1.
Study Quality
Details of study methodology were generally poorly
reported, therefore, limiting our ability to assess study
quality (see Table 2). Only four studies fulfilled all five
criteria, that is, used a prospective design, recruited
consecutive or all eligible patients, provided an explicit
description of inclusion and exclusion criteria, blinded
outcome assessment or used a third party assessor, and
reported a loss to follow of 20% or less [lvi, xxxviii,
lxix, lxx]. The overall quality of studies was in general
relatively poor with a median quality score of 2 out of a
potential maximum score of 5. There was evidence of an
increase in quality score over time (ie, median quality
score of studies published in 1980–1989: 1 vs.1990–
1999: 2 vs. 2000 or later: 3).
Level of Pain Relief with SCS
A total of 63 studies reported the proportions of
individuals with CBLP patients experiencing pain relief
following SCS. Only four studies reported percentage
pain relief in the leg or back or both [ii, lxv, lxvii, lxx].
The majority of studies (59/63), therefore, assessed and
reported generic pain relief, that is, undifferentiated by
back or leg location. For the purpose of our between-
study analysis, the results of all 63 studies were
pooled.
There was evidence of substantial statistical hetero-
geneity in the level of pain relief at longest follow-up
across studies (v2 statistic: 402.91, P < 0.0001, I2
Updated electronic searches
Titles & abstracts N=992
Excluded
N=906
Spine 2005 Review
N=78 studies
Excluded N=65
Not SCS N=13
Abstract only N=4
Review N=12
Non-English language N=2
No pain outcome reported 
N=13
Mixed series no disaggregate 
results N=12
Economic evaluation N=5
Case report N=2
Dual publication N=2
Full papers reviewed
N=86
Excluded N=21
Non-English language 
N=8
Abstract only N=5
Wrong indication N=2
Not SCS N=1
Mixed series no 
disaggregate results 
N=2
Not located N=3
Included 
N=18 studies (N=21 papers)
Final included N=74 (77 papers)
RCTs N=4
Non-RCT N=2
Case series N=68
Included 
N=56 studies (N=56 papers)
Figure 1. Summary of study selection.
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statistic: 85%). Overall, 58% (95% confidence interval
(CI): 53% to 64%, random effects) of patients with
CBLP achieved pain relief (see Figure 2). Studies used a
range of definitions of pain relief that included objective
cut-offs (eg, ≥ 50% reduction in pain) and subjective
cut-offs (eg, “satisfactory”, “good” or “excellent” pain
relief). However, the level of pain relief with SCS
appeared consistent when limited to those 32 studies
that used an objective definition (53%, 95% CI: 47% to
59%, random effects).
There was evidence of small-study bias and potential
publication bias as evidenced by funnel plot asymmetry
(see Figure S1) and a significant Egger test (P = 0.003).
Eleven studies (12 comparisons) reported pain score
before and after SCS data appropriately to allow meta-
analysis [ii, lvii, lviii, lix, lx, lxi, lxv, lxix, xliii, lxxv,
lxxvii]. There was evidence of significant statistical
heterogeneity (v2 statistic: 237.8, P < 0.0001, I2 statis-
tic: 95%) across studies. The mean reduction in pain
score (on 0–10 scale) with SCS across studies was 3.3
(95% CI: 3.9 to 2.7, random effects; see Figure 3).
There were insufficient studies to examine the associa-
tion between patient and device-related factors and the
change in pain score with SCS.
Meta-Regression and Stratified Meta-analysis
In univariable meta-regression analysis, the only study
level factor to be associated with level of SCS pain relief
was the mean duration of pain (P = 0.011; see Table 3).
An increasing mean duration of pain across studies was
associated with a reduction in the level of SCS pain relief
—each 12-month increase in the duration of pain
reduced the level of pain relief by ~2.0% (see Figure 4).
Figure 5 shows a meta-analysis stratified by the
location of CBLP pain. There appeared a higher level
of pain relief with studies in individuals with predom-
inantly back pain compared with studies in those with
predominantly leg pain (see Figure 5). However, the
number of studies contributing data to this analysis was
small [ii, xvi, lxx], and no significant statistical associ-
ation with pain relief and the location of CBLP was seen
in either univariable or multivariable meta-regression.
In multivariable analysis, no study- or patient- or
technology-related characteristics were seen to be
significant predictors of pain relief following SCS
(see Table 3).
Table 1. Selected Characteristics of the Included Studies
(n = 74)
Characteristic*
Number of Studies (%)
or Median (range)†
Sample size 29 (1–196)
Publication date
1980–1989 26 (35%)
1990–1999 24 (32%)
2000–2009 17 (23%)
2010-present 7 (9%)
Study location
North America 35 (47%)
Europe 36 (49%)
Other 3 (4%)
Setting
Single centre 58 (78%)
Multi centre 16 (22%)
Mean age (n = 59) 50 (43–70)
Gender (% male; n = 53) 52 (27–86)
Previous back operation (% patients; n = 64) 100 (0–100)
Duration of pain before SCS (months; n = 40) 85 (6–180)
Pain score before SCS (0–10 scale; n = 25) 7.8 (2.7–8.4)
Location of CBLP
Predominantly back 4 (5%)
Predominantly leg 9 (12%)
Mix of back and leg 22 (20%)
Not reported 39 (53%)
Workers compensation/insurance
In all or a proportion of patients 8 (12%)
Not reported 66 (89%)
SCS lead placement
Percutaneous lead only 23 (31%)
Surgical lead only 19 (25%)
Both percutaneous & surgical 13 (17%)
Lead
Not reported 20 (27%)
Duration of follow-up (months; N = 66) 24 (1–65)
Outcomes reported
Pain relief 63
Pain score 12‡
All SCS-related complications 7
Complications requiring intervention 13
*N = 74 unless otherwise stated.
†Median and range of study means.
‡Report appropriate data to allow meta-analysis.
Table 2. Quality of Included Studies (n = 74)
Criteria
Frequency of Studies (%)
Yes No
Not
Reported
Design: Prospective
design
20 (27%) 20 (27%) 34 (46%)
Population selection:
All eligible or consecutive
patients
19 (25%) 0 54 (75%)
Population description:
Explicit inclusion/exclusion
criteria*
34 (45%) 40 (55%) NA
Outcome assessment:
Blinded or independent
14 (19%) 2 (3%) 58 (78%)
Attrition: ≤ 20% drop
out/loss to follow-up
47 (63%) 8 (5%) 23 (32%)
Quality score†
Median (range) 2 (0–5)
*Defined as sufficient detail to be able to differentiate whether included patients with
CBLP had predominantly leg pain, predominantly back pain, or a mix of leg and back
pain.
†Number of quality criteria met (0–5).
CBLP, chronic back and leg pain; NA, not applicable.
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 84.6%, p = 0.000)
North (1991a)
North (2005c)
Vogel (1986)
Kumar (1991)
Neilson (1975)
Duyvendak (2007)
North (1991b)
Spiegelmann (1991)
Mittal (1987)
North (2005a)
Sheldon (1975)
Simpson (1989)
Meglio (1989)
Turner (2010)
Long (1975)
Study
Mironer (2008)
Meilman (1989)
Richardson (1982)
Kumar (2007)
Leclercq (1982)
Kumpulainen (1986)
Vonhogen (2011)
Kavar (2000)
Barolat (1999)
North (1977/78)
Leibrock (1984)
Ray (1975)
Probst (1990)
Kumar (1986)
DeLaPorte (1983)
Sears (2011)
Hoppenstein (1975)
Kim (1994)
Leveque (2001)
Devulder (1991)
ID
LeDoux (1993)
Hunt (1975)
North (2005b)
Devulder (1997)
Kumar (1998)
Shatin (1986)
Law (1992)
Reig (2009)
Fuime (1995)
Meglio (1994)
Seijo (1993)
Blume (1981)
Rainov (1996)
Mundinger (1982)
Clark (1975)
Kay (2001)
Van der Kleft (1994)
Waisbrod (1985)
DeVos (2012)
Pineda (1975)
DeLaPorte (1993)
Hassenbusch (1995)
Burchiel (1995)
Dario (2001)
Devulder (1990)
Siegfeld (1982)
Barolat (2001)
Bel (1991)
58.43 (53.25, 63.62)
52.00 (37.42, 66.34)
92.31 (63.97, 99.81)
50.00 (15.70, 84.30)
64.91 (51.13, 77.09)
40.57 (31.13, 50.54)
70.00 (45.70, 88.10)
48.00 (33.66, 62.58)
41.67 (15.17, 72.33)
38.71 (21.85, 57.81)
37.50 (18.80, 59.41)
66.67 (9.43, 99.16)
57.14 (18.41, 90.10)
10.53 (1.30, 33.14)
51.16 (35.46, 66.69)
16.33 (7.32, 29.66)
59.26 (45.03, 72.43)
60.00 (36.05, 80.88)
100.00 (54.07, 100.00)
40.48 (25.63, 56.72)
55.00 (31.53, 76.94)
100.00 (39.76, 100.00)
50.00 (27.20, 72.80)
78.26 (56.30, 92.54)
100.00 (69.15, 100.00)
75.00 (53.29, 90.23)
57.14 (28.86, 82.34)
48.47 (41.29, 55.70)
63.39 (53.76, 72.29)
52.63 (35.82, 69.02)
52.94 (27.81, 77.02)
29.40 (10.30, 55.90)
100.00 (73.54, 100.00)
68.75 (53.75, 81.34)
50.00 (24.65, 75.35)
19.51 (8.82, 34.87)
Percentage (95% CI)
37.50 (8.52, 75.51)
20.00 (0.51, 71.64)
33.33 (15.63, 55.32)
32.56 (19.08, 48.54)
52.73 (44.82, 60.54)
70.00 (59.43, 79.21)
70.94 (61.83, 78.96)
50.77 (38.07, 63.40)
57.14 (39.35, 73.68)
61.90 (38.44, 81.89)
64.71 (46.49, 80.25)
70.00 (45.72, 88.11)
86.21 (68.34, 96.11)
100.00 (2.50, 100.00)
67.00 (22.28, 95.67)
58.06 (39.08, 75.45)
67.31 (52.89, 79.67)
75.00 (47.62, 92.73)
70.70 (54.40, 83.90)
46.43 (32.99, 60.26)
56.25 (43.28, 68.63)
66.67 (29.93, 92.51)
55.00 (38.49, 70.74)
91.30 (71.96, 98.93)
73.91 (51.59, 89.77)
37.08 (27.07, 47.97)
86.67 (59.54, 98.34)
45.45 (16.75, 76.62)
0 25 50 75 100
Figure 2. Meta-analysis of pain relief following SCS.
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Within-study Analysis
Back vs. Leg Pain Outcome. Ten SCS studies reported
both back and pain leg outcomes following SCS in
the same individuals [ii, lix, lx, lxv, lxvii, lxx, xxxix,
lxxiii, lxxvi, lxvii, lxx, xxxix, lxxiii, lxxvi, lii] (see
Table 4). In the four studies in which pain was
predominantly leg, three reported a higher level of
pain relief for the leg than the back [lxv, xxxiv, lxx].
The fourth, a study in patients with FBSS on worker’s
compensation, found only a small reduction in leg
pain relief up to 24-months, while the level of back
pain got worse following SCS [lxxvi]. The one study
undertaken in those with predominant back reported
similar levels of pain relief at 6 and 24-months post-
SCS in both leg and back [ii]. Consistent with this,
the five studies with either mixed leg and back pain
or a nondefined location of CBLP observed a similar
magnitude of pain relief in the legs and back
following SCS [lix, lxvii, lx, lxxiii, lii].
Device-related Factors. Seven studies examined the
association between device-related aspects of SCS and
pain relief [xi, xxi, xxvii, lxvii, xxxvii, lxix, xli] (see
Table 5). North et al. found that patients with FBSS
with predominant leg pain randomized to lead place-
ment by laminectomy experienced better pain relief than
those allocated to percutaneous lead placement [lxix].
This observation was confirmed by a nonrandomized
study [xxvii]. A single-center review of 182 individuals
with FBSS over an average of 8.8 years follow-up
Study (year) [location of CBLP pain/location of pain assessment] 
Weighted pooled estimate shown as diamond as bottom of plot
NOTE: Weights are from random effects analysis
Overall  (I-squared = 95.4%, p = 0.000)
Spincemaille (2004) [mixed/undefined pain]
Turner (2010) [leg/leg pain]
Burchiel (1995) [mixed/undefined pain]
De Vos (2012) [mixed/leg pain]
Moriyama (2012) [undefined/undefined pain]
De Mulder (2005) [undefined/leg pain]
Barolat (2001) [back/undefined pain]
De Vos (2012) [mixed/back pain]
ID
Duyvendak (2007) [mixed/undefined pain]
Kumar (2007) [leg/leg pain]
Rainov (1996) [mixed/undefined pain]
Costantini (2010) [mixed/undefined pain]
Study
-3.34 (-3.94, -2.74)
-4.30 (-4.62, -3.98)
-1.40 (-1.83, -0.97)
-2.00 (-2.55, -1.45)
-4.80 (-5.27, -4.33)
-3.10 (-4.39, -1.81)
-5.00 (-6.07, -3.93)
-2.60 (-3.63, -1.57)
-2.80 (-3.21, -2.39)
Difference (95% CI)
-3.40 (-3.85, -2.95)
-2.67 (-4.04, -1.30)
-3.30 (-3.48, -3.12)
-4.60 (-4.95, -4.25)
Mean
Reduction in Pain Increase in Pain 
0-10 -5
Figure 3. Meta-analysis of change in pain score (0–10 scale) with SCS.
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reported differences between SCS devices in “time to
failure”; a composite outcome taking into account trial
stimulation failure, device complication, and loss of pain
relief [xxi]. One study found multichannel stimulation
parameters to be associated with a higher level of pain
relief than a simple bipolar stimulation [xxxvii], while
another found patients reported no difference between
the two forms of stimulation [lxvii]. Pineda et al. found
no difference in the proportions of patients reporting
satisfactory or excellent pain relief between those who
had received a unipolar electrode compared with those
who got a bipolar electrode [xli].
Patient-Related Factors. Eight studies reported the
association between patient characteristics and pain
relief following SCS [lvii, vi, lxiii, xxi, lxv, xxxvii,
xxxvii, xli] (see Table 6). The study by Dario et al.
reported higher levels pain relief with SCS in 10
individuals with predominant leg pain compared to 14
with leg only pain [vi]. Similarly, Pineda et al. found that
of the individuals with back pain only, none achieved a
satisfactory level of back pain relief following SCS [xli].
This compared with 40% of those with only leg and
49% of those with both leg and back. While, Kumar and
colleagues [xxi] found a significant association between
the time since back operation and pain relief with SCS
(those with shortest time since operation having the
greatest level of pain relief), three other studies reported
no such association [lvii, lxiii, xxxvii]. No other patient-
level characteristics were consistently found to be related
to the level of pain relief following SCS.
DISCUSSION
This systematic review of evidence base on pain relief
following SCS quantifies the association between the level
of pain relief and patient and technology-related factors.
Table 3. Meta-Regression Analysis of Included Studies Reporting SCS Pain Relief (n = 59)
Predictors*
Univariable Coefficient
(95% CI) P value
Multivariable† Coefficient
(95% CI) P value
Study characteristics
Continent 0.5 (5.6 to 4.5) 0.83 11.1 (26.4 to 4.2) 0.36
Sample size 0.1 (0.2 to 0.1) 0.40 0.1 (1.4 to 126) 1.00
Publication year 0.2 (0.3 to 0.7) 0.46 2.4 (4.6 to 43.1) 0.15
Setting‡ 0.1 (13.1 to 13.4) 0.99 7.6 (43.4 to 58.5) 0.99
Comparative design§ 0.2 (17.4 to 17.0) 0.98 2.3 (39.9 to 35.4) 1.00
Quality score¶ 0.4 (3.6 to 4.3) 0.86 1.1 (2.6 to 0.4) 0.36
Follow-up duration (56) 0.3 (0.7 to 0.06) 0.10 0.07 (1.9 to 2.0) 0.93
Baseline VAS pain (16) 0.3 (10.3 to 10.0) 0.95 4.9 (26.1 to 16.2) 0.96
Patient characteristics
Mean age (49) 1.4 (2.8 to 0.04) 0.06 1.8 (2.4 to 6.1) 0.26
Percent male (43) 0.1 (0.3 to 0.5) 0.56 1.0 (0.3 to 2.3) 0.30
Percent postop (53) 0.1 (0.5 to 0.8) 0.71 k
Duration of pain (33) 0.2 (0.3 to 0.05) 0.011 0.02 (0.5 to 0.6) 0.92
CBLP location** (29) 4.0 (15.8 to 7.7) 0.49 k
Worker’s compensation (60) 1.9 (16.2 to 20.0) 0.84 k
SCS characteristics
Lead placement (47) 3.2 (4.8 to 11.4) 0.42 k
*N = 59 studies included unless otherwise stated.
†Based on N = 12 studies and P value adjusted for multiple testing.
‡Single centre vs. multicentre.
§Controlled vs. case series.
¶Number of quality criteria met (0–5).
kStudies dropped due to colinearity.
**Predominantly leg vs. predominantly back vs. mixed.
0
20
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80
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Mean duration pain (months)
Figure 4. Plot of between study association of mean duration of
pain vs. level of SCS pain relief.
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Our review included 74 studies in a total of 3,025
individuals with CBLP, the majority of which were post
back surgery (ie, patients with FBSS). We found a
substantial number of individuals experience important
levels of pain reduction following SCS, that is, 53%(95%
CI: 47% to 60%) achieving an equivalent of 50% more
pain relief at a mean follow-up of 24 months. This is
supported by a magnitude of reduction in pain score (on
0–10 scale) with SCS studies of 3.3 (95% CI: 3.9 to
2.7) that indicates a clinically important change (ie, a
change of 2 or more units on 0–10 scale27,28). Although
there was considerable heterogeneity across studies, we
found no strong evidence that pain relief with SCS was
limited to particular patients with CBLP subgroups. The
one exception was the duration of pain, that is, those
studies with the longest mean duration of pain reported a
smaller magnitude of pain relief following SCS. How-
ever, we need to be cautious in this interpretation as this
study level association was not seen in multivariable
analysis, that is, adjusting for other study level charac-
teristics. Two studies have shown that patients with FBSS
receiving a surgical lead placement by laminectomy have
superior analgesic outcomes compared with those who
received a percutaneous lead placement.13,29
It is believed that SCS may be a more successful
therapy for CBLP in those who present with pain
predominantly in the legs than the low back.12–14 While
we sought to quantitatively explore the association
between the level of SCS pain relief and the location of
pain, because of the quality of reporting of the majority
of included studies (few studies reported either the
precise details of the location of pain pre-SCS, the pain
outcome in both leg and back post-SCS), we were only
able to partially do so. Although contemporary studies
are better, only a minority of studies provide sufficient
description of the entry criteria and assessment of
participants to be able to reliably determine the location
of their CBLP. Additionally, few studies have reported
data on the level of pain relief in both the legs and the
back. Accepting these limitations, SCS appears to be
effective in reducing CBLP irrespective of back or leg
pain location. Although increasing in the number, fewer
SCS studies to date have reported outcomes of SCS in
predominantly back pain populations. We identified no
Predominantly back pain [n=3 studies]
Predominantly leg pain [n=8 studies]
Both back & leg pain [n=18 studies]
Undefined [n=34 studies]
ID
Study
86.00 (75.00, 96.00)
54.00 (39.00, 68.00)
63.00 (53.00, 72.00)
54.00 (48.00, 61.00)
Percentage (95% CI)
feileRniaP%
0 25 50 75 100
Figure 5. Stratified meta-analysis—pain relief following SCS by location of CBLP.
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randomized controlled evidence of SCS in this subpop-
ulation.
Comparison with Previous Reviews
The level of pain relief seen in this update review is
consistent (ie, the 95% CIs overlap) with the findings of
our 2005 meta-analysis—62% (95% CI: 56% to 69%)
achieving an equivalent of 50% or more pain relief
following SCS at a mean follow-up of 26 months.11 In
this present study, we only found the duration of pain to
be predictive of the level of pain relief following SCS,
while the previous meta-analysis identified a number of
predictors (ie, duration of study follow-up, type of pain
[CBLP vs. FBSS] and study setting [single vs. multicen-
ter]). This difference probably reflects the somewhat
different evidence base between the two analyses—we
excluded some studies from the previous review (eg,
abstracts only, mixed case series that did not specifically
report outcomes in those with CBLP) and a number of
studies, published since, have been included in this
review.
Previous systematic reviews of SCS for CBLP have
not formally quantified the difference in level of pain
relief with SCS according to the location of CBLP or
whether pain assessment was specific to either the legs or
back or aspects of SCS technological innova-
tion.5,11,17,18,30 However, a number of these issues have
been qualitatively reviewed in the “Pain Practice Param-
eters for the Use of Spinal Cord Stimulation in the
Treatment of Chronic Neuropathic Pain” report.9 This
report gave a “level B” recommendation (ie, uncertain
validity) that pain is most likely to be treated success-
fully by SCS if: “The pain location is radicular or
radiating than axial in distribution (predominant low
back pain is more difficult to treat)….”.
Strengths and Limitations
We made every effort to reduce potential bias in this
review. We used comprehensive electronic searches,
including the searching of reference lists of included
studies and previous reviews. However, we did find
evidence of small-study bias that may reflect some level
of publication bias. By including only studies that
reported pain outcomes in CBLP individuals, we sought
to minimize confounding due to the effects of SCS on
other indications. We found several potential biases in
the included studies: methodological details were often
poorly reported with respect to the use of prospectiveTa
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Table 5. Within Study Assessment: SCS Procedure-Related Predictors
Study Design Comparison
Population and period of
follow-up Findings Comment
Devulder (1997)xi Case series Battery type 69 FBSS
Location of pain undefined
Mean follow-up 30 month
Complications*
Radiofrequency: 23/27
(85%)
Internalized battery: 25/42
(53%) P = 0.02†
*Electrode reinterventions
†P value calculated by
authors of this report
Kumar (1998)xxi Case series Type of electrode 182 chronic postlaminectomy
pain
Location of pain undefined
Mean follow-up 8.8 year
Time to failure*
Resume & Pisces-
Quadripolar electrodes
significantly more reliable
than Pisces-Sigma
electrodes (hazard
ratio = 0.49, P < 0.001;
hazard ratio = 0.45,
P < 0.01,
respectively). No significant
difference in reliability
Resume vs. Pisces-
Quadripolar systems.
*Failure of trial stimulation,
device complication, loss of
pain relief
Leveque (2001)xxvii Case series Implant technique 23 FBSS
Location of pain undefined
Mean 34 month follow-up
Pain relief*
Laminectomy 12/14 (86%)
Pecutaneous 6/9 (67%),
P = 0.28
Postop pain score
Laminectomy mean 4.6
(range 0–9)
Pecutaneous mean 6.1
(range 0–10)
*Excellent or good pain
relief
Mironer (2008)lxvii Case series Stimulation
parameters
54 chronic low back and/or
lower extremity pain
Location of pain undefined
Mean 9.3 month
Pain relief*
Single stimulation: 6/9
(65%)
Multi stimulation: 25/44
(56%) P = 0.58†
*50% pain relief
†P value calculated by
authors of this report
North (1991b)xxxvii Case series Type of electrode 50 FBSS
Location of pain undefined
Mean follow-up 5.0 years
Success*
Programmable
multichannel implants
significantly better than
simple bipolar electrodes
(coefficient+; 1.231,
P = 0.047)
*≥ 50% pain relief and
patient satisfaction
+logistic regression
North (2005b)lxix RCT Implant technique 24 FBSS
Leg pain ≥ back pain
Up to 2.9 years follow-up
Success*
Mean 1.9 years follow-up
Laminectomy 10/12 (83%)
Pecutaneous 5/12 (42%),
P = 0.04
Mean 2.9 years follow-up
Laminectomy 5/12 (42%)
Pecutaneous 3/12, (25%)
P = 0.91
Activities of daily living
“Improvement greater with
laminectomy. Not
statistically significant”+
Complications
Percutaneous 5/12 (42%)
Laminectomy 1/12 (8%)
*≥ 50% pain relief and
patient satisfaction
+ no inferential statistics
reported
Pineda (1975)xli Case series Type of electrode 56 unsuccessful lumbar disc
surgery
Back, leg, and mix of back
and leg pain
Follow-up duration not
reported
Pain relief*
Unipolar: 14/28 (50%)
Biopolar: 12/28 (43%),
P = 0.59†
* “satisfactory” or
“excellent” pain relied (no
definition)
†P value calculated by
authors of this report
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Table 6. Within Study Assessment—Patient Characteristics
Study Design Comparison
Population & Period of
Follow-up Findings Comment
Burchiel
(1995)lviii
Case series Age, gender, education, pain,
compensation for injury,
prior back operations,
duration of pain
40 chronic leg & back pain
Mix of leg and back pain
Mean follow-up 5.6 year
Pain relief*
age r2 = 0.53, P = 0.004 +
gender r2 = 0.17, P = 0.17 +
pain location r2 = 0.23,
P = 0.3 +
compensation r2 = 0.11,
P = 0.5 +
pain operations r2 = 0.29,
P = 0.1 +
pain duration r2 = 0.09,
P = 0.6+
*≥ 50% pain relief and
patient satisfaction
+multivariate
regression-based
analysis
Dario
(2001)vi
Non RCT Location of CBLP 24 FBSS
Mix of leg and back pain
Follow-up to 84 month
Pain score*
Leg only pain (n = 14)
Pre-SCS pain: mean 85
(range 77–92)
Post-SCS pain: mean 22
(range 17–24)
Predominant leg pain
(n = 10)
Pre-SCS pain: mean 45
(range 39–50)
Post-SCS pain: mean 40
(range 36–45)
“P < 0.01 between groups”
Fiume
(1995)lxiii
Case series Number of surgical
operations, duration and
severity of symptoms, time
since first operation,
gender, pain location
55 FBSS with radicular
pain
Location of pain not
reported
Mean follow-up 55
month
Pain relief*
“There was no relationship
between the success rate
and number of surgical
operations, duration and
severity of symptoms, time
since first operation.”
Female: 15/22 (69%)
Male: 13/31 (43%) P = 0.06†
“patients with predominant
pain did better”
*≥ 50% pain relief
†P value calculated by
authors of this report
Kumar
(1998)xxi
Case series Age
Gender
Number of previous back
operations
Time since last back
operation
Worker’s compensation
182 chronic
postlaminectomy pain
Location of pain not
reported
Mean follow-up 8.8 year
Successful pain relief*
< 51 years: 48/91 (53%)
> 51 years: 39/74 (53%)
P = 0.99†
Male: 74/140 (53%)
Female: 13/25 (52%)
P = 0.94†
1: 9/29 (47%)
2: 23/40 (58%)
3: 26/56 (46%)
4: 14/24 (48%)
> 4: 15/26 (58%) “no
correlation”+
0–3 month: 17/18 (94%)
3–6 month: 31/39 (79%)
6–9 month: 22/40 (55%)
9–12 month: 14/36 (40%)
> 12 month: 3/39 (9%),
regression coeff. 0.86,
P < 0.05
Workers comp claim: 30/56
(54%)
No workers comp: 57/109
(52%) P = 0.88†
*50% pain relief
†P value calculated by
authors of this report
+no inferential statistics
reported
Kumar
(2007)lxv
RCT Number of previous back
surgeries
94 FBSS
Leg > back pain
Follow-up 6 mo
Pain relief*
< 3 vs. ≥ 3: P = 0.95 +
trend favoring < 3
*≥ 50% pain relief
+Subgroup analysis
(interaction test
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design, population selection, and independent outcome
blinding. Therefore, there was potential for selection
and assessment bias.
As outlined above, the principle limitation of this
study was the failure by more than half of the included
studies to report sufficient details to enable us to assess
the factors that may be predictive of pain relief,
including the precise location of pain. CBLP and FBSS
are heterogeneous descriptors; identification of specific
pain predictors can allow stratification of this broad
group of patients and, thereby, the optimization of
therapy. Another limitation is the risk of ecological
fallacy with meta-regression. An association between
pain relief and patient and technology factors at a study
level may not reflect such an association within a study
and, therefore, at the level of individual with CBLP. To
overcome such criticism, we used multivariable analysis;
therefore, adjusting for what might be potential con-
founders. Additionally, we have reported within-study
analyses to check whether they were consistent with our
meta-regression analysis.
Implications
A number of international clinical guidelines currently
recommend SCS as evidence-based treatment for
the management of CBLP following back surgery
(ie, FBSS).7,9,30 The PROCESS trial reported that 24%
(n = 51) of 214 preselected individuals with FBSS did
not enter the trial specifically because of their predom-
inant lower back pain component.1 Targeting and the
effective management of axial back pain has become a
focus for recent technological innovation in neuromod-
ulation. This has seen the development and use of
multipolar SCS electrodes, hybrid peripheral nerve
stimulation systems, and alternative stimulation tech-
niques.12 Well-conducted trials, using contemporary
technological advances in neurostimulation, in individ-
uals with predominant back pain, are needed. Future
publications need to better report inclusion and screen-
ing processes in sufficient detail to allow a better
understanding of factors that may predict the success
of SCS, including details on the technology used, the
precise location of pain location, pain duration, and
level of opioid prior to therapy. In addition to the
assessment of patient-related outcomes, such as health-
related quality of life and functional capacity, studies
should collect pain outcomes in both the leg and back, to
enable better understanding of the target of neurosti-
mulation.
We are aware of two randomized trials of SCS
currently being undertaken in back pain. The first is a
Table 6. (Continued)
Study Design Comparison
Population & Period of
Follow-up Findings Comment
Duration of diagnosis of
FBSS
< 12 vs. ≥ 12 months:
P = 0.20 +
^includes both SCS and
usual medical care
intervention received
North
(1991b)xxxvii
Case series Gender, duration of follow-
up, time since 1st operation,
number of previous
operations, pain location
50 FBSS
Location of pain not
reported
Mean follow-up 5.0 year
Success*
Males significantly poorer
than simple bipolar
electrodes (coefficient+;
1.231, P = 0.047)
“No significant association
for duration of follow-up,
time since 1st operation,
number of previous
operations, pain location
(axial vs. radicular)”
*≥ 50% pain relief and
patient satisfaction
+logistic regression
North
(2005a)xxxviii
RCT Age, gender, number of
previous operations,
workers compensation
50 FBSS
Back > leg pain
Mean follow-up 2.9 year
Success*
“No association of age,
gender, number of
previous operations,
workers compensation
with outcome”
*≥ 50% pain relief and
patient satisfaction
Pineda
(1975)xli
Case series Location of pain 56 unsuccessful lumbar
disc surgery
Duration of follow-up
not reported
Pain relief*
Back pain: 0/6 (0%)
Leg pain: 2/5 (40%)
Leg & back pain: 22/45
(49%)
*Excellent or satisfactory
pain relief
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multicenter French study that aims to compare the anal-
gesic efficacy of mono-column SCS (using longitudinal
and transverse electric stimulation) versus mono-column
SCS (using axial stimulation, represented by quadripolar
or octopolar lead; ESTIMET, NCT01628237). A total
of 115 patients with lumbar pain will be randomly
allocated to each of the SCS approaches and their leg
and back pain, function, level of depression, health-
related quality, and costs at 6- and 12-month postran-
domization. Second, a multi-country randomized trial
(PROMISE, NCT01697358) is ongoing. Two hundred
and twelve patients with FBSS presenting with predom-
inant back pain will be randomized to SCS using a
tripolar 16-contact lead plus optimal medical manage-
ment as compared to optimal medical management
alone in a postoperative CBLP population with pre-
dominant back pain. This parallel designed trial aims to
assess outcomes at 6 to 24-months including leg and
back pain relief, health-related quality of life, functional
capacity, and costs.
CONCLUSIONS
This systematic review and meta-analysis supports SCS
as an effective pain relieving treatment for CBLP in
patients with or without a prior history of back surgery
and presenting as predominantly leg pain. Randomized
controlled trials are needed to confirm the effectiveness
and cost-effectiveness of SCS in the CBLP population
with predominant low back pain and examine patient
and technology-related factors that may be predictive of
SCS success.
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